Adebrelimab and oral etoposide for older or frail patients with small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a combination of the immunotherapy drug Adebrelimab with oral chemotherapy (etoposide) for people with small cell lung cancer who are older (65+) or have a weaker health status (ECOG score 2-3). The goal is to see if this treatment is safe and effective for those who may not be eligible for more aggressive standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 65 years or older, or your ECOG performance status (a measure of daily living ability) is 2-3 (meaning you can still care for yourself but are unable to do heavy work).
- You have extensive-stage or locally advanced small cell lung cancer that has spread or is too large to remove surgically.
- You have at least one measurable tumor that can be tracked with scans.
- Your vital organs (bone marrow, liver, kidneys, heart) must work well enough based on blood tests and an echocardiogram (heart ultrasound).
- You are willing to use effective birth control during the study and for 6 months after the last dose (if you could become pregnant or father a child).
- You can swallow pills and do not have a condition that prevents your body from absorbing oral medicine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three drugs (bevacizumab, anlotinib, and etoposide) as a first treatment for patients with metastatic small-cell lung cancer who are 65 or older, or who cannot tolerate standard intensive chemotherapy. The goal is to see if this gentler approach can effectively control the cancer while being safer for these patients.
This trial tests a new immunotherapy drug (Adebelimab) combined with standard chemotherapy as a first treatment for extensive-stage small cell lung cancer. The goal is to see if this combination works better than chemo alone.
This trial tests a combination of the immunotherapy drug adebrelimab with standard chemotherapy and radiation for people with a rare type of esophageal cancer called small cell carcinoma. The goal is to see if this approach can help shrink or control the tumor.
This trial tests adding a drug called adebrelimab (a type of immunotherapy) before surgery for people with early-stage small cell lung cancer that can be removed. The goal is to see if it helps shrink the tumor and improve outcomes.
This trial tests a combination of immunotherapy (adebrelimab), a targeted therapy (apatinib), and chemotherapy given before surgery for people with limited-stage small cell lung cancer. The goal is to see if this treatment shrinks the tumor enough to make surgery more effective and to study markers that might predict response.
This trial tests a new immunotherapy drug called adebrelimab combined with standard chemotherapy and radiation for people with limited-stage small cell lung cancer. After the initial treatment, adebrelimab is continued alone to help prevent the cancer from coming back.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.